ArticleInternational journal of clinical pharmacy2024

Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.

Yingdan Cao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.